MedTrace Logo

Breast Cancer, Sexuality and Black Cohosh

NCT02467686 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2017-03-20

No results posted yet for this study

Summary

The purpose of this study is to evaluate the Cimicifuga racemosa effects on the sexuality of women with Breast cancer using tamoxifen or aromatase inhibitor through questionnaires.

Conditions

  • Sexuality

Interventions

BEHAVIORAL

WHOQOL questionnaire

WHO defines Quality of Life as individuals perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards and concerns.

BEHAVIORAL

FSFI questionnaire

FSFI questionnaire application for evaluation of sexual function at the first visit, 3-month and 6-month follow-up.

BEHAVIORAL

kupperman scale

Kupperman scale is a tool to help evaluate the severity of menopausal symptoms

DRUG

Cimicifuga racemosa

The Cimicifuga racemosa effects on the sexuality of women with Breast cancer

DRUG

tamoxifen

The Cimicifuga racemosa effects on the sexuality of women with Breast cancer using tamoxifen

DRUG

exemestane

The Cimicifuga racemosa effects on the sexuality of women with Breast cancer using aromatase inhibitor.

Sponsors & Collaborators

  • Irmandade da Santa Casa de Misericordia de Sao Paulo

    lead OTHER

Principal Investigators

  • Black cohosh · Irmandade da Santa Casa Misericordia Sao Paulo

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
48 Years
Max Age
68 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2017-09-30
Completion
2017-12-31

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02467686 on ClinicalTrials.gov